Europe Bioreactors Market Share to Reach USD 850 Mn By 2025

 Request a sample

According to the Graphical Research new growth forecast report titled Europe Bioreactors Market By Technology (Wave-induced Motion SUB, Stirred SUB, Single Use Bubble Column), By Molecule (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Stem Cells, Gene Therapy)  By End-use (R&D Organizations, Biopharma Manufacturers, CMOs), By Cell (Mammalian Cells, Bacterial Cells, Yeast Cells), Industry Analysis Report, Country Outlook (Germany, UK, Spain, Italy, France, The Netherlands, Denmark, Russia, Poland, Sweden, Norway) Estimated to collect USD 850 million by 2025.

Europe bioreactors industry is largely driven by technological advancements related to bioreactor material, design and processing. Various technological innovation such as continuous manufacturing, process analytical technology, and single-use systems in bioreactors contribute to advancements in biological processes. Hence, the above-mentioned reasons will augment bioreactors market growth over the forecast timeframe. 

The bioreactors market is expected to witness considerable growth across the forecast timeframe owing to rising biopharmaceutical industry. The growth of biopharmaceutical industry can be attributed to increased investment in technological developments, especially in the targeted and personalized therapies, rising prevalence of chronic diseases, and growing geriatric population. Moreover, orphan drugs offer an integrated healthcare solution that enables biopharma industry to develop new areas of patient support, therapeutics, treatment, diagnosis, and monitoring. The number of FDA designations of orphan drugs has increased steadily over the past decade, thus augmenting bioreactors market growth.

However, vulnerability to leaching, regulatory concerns regarding single-use bioreactor and limited storage capacity should hinder bioreactor market growth. Additionally, large-scale disposal of plastic derivatives is a growing environmental concern restraining the business growth over the forecast years.

Bacterial cells segment is estimated to expand at 16.9% CAGR over the forecast timeframe. Bacterial cells are robust and not prone to damage. It provides bioreactors with the high mass transfer competence, permit rapid metabolism, and supports high-cell density microbial cell cultivation and growth in the quantity of product. Recombinant proteins can also be produced through bacterial cells. Hence, the above-mentioned factors will propel bacterial cells segmental growth.

Recombinant protein segment generated over USD 34.9 million in 2018. High growth is attributed to growing applications of recombinant proteins in the treatment of several diseases, including rheumatic conditions, and different types of cancer. The recombinant protein segment has grown at a significant rate, demonstrating an economically robust future for the bioreactors market.

Stirred SUBs segment is expected to witness substantial growth rate of 17.1% across the forecast timeframe, owing to extensive use in modern biotechnological processes. The stirred SUBs are widely used for mammalian cell cultures such as production of monoclonal antibodies (mAbs), and vaccines. They have several advantages such as short turnaround times and reduced risk of cross contaminations. Hence, the aforementioned reasons will positively drive segmental growth.

Biopharma manufacturers segment was valued at USD 88.9 million in 2018 and is projected to witness strong growth over the forecast years. High growth is attributed to increase in the number of biopharmaceutical products in pipeline including with growing establishment of new facilities to meet the production needs. Furthermore, large biopharmaceutical companies and biosimilar producers are entering strategic collaborations with new entrants to facilitate business expansion.

Germany is estimated to hold major chunk of revenue share of 25.9% in 2018 and is anticipated to grow at a significant growth rate in the coming years. Increasing number of biopharmaceutical companies responsible for bringing new medicines to patients and their collaborations with venture capital firms, academic institutions, and patients will accelerate the Europe bioreactors market during the forecast period. 

Major market players in Europe bioreactors market are Applikon Biotechnology, Inc., Bbi-biotech, Cellexus Limited, CerCell Aps, Eppendorf AG, GE Healthcare, GEA Group Aktiengesellschaft, Merck Group, Pierre Guerin Sas, Sartorius Stedim Biotech Group, Solaris Biotech Solutions and Thermo Fisher Scientific Inc. These market players are undertaking strategies such as technology development and acquisitions to gain market presence and for company expansion.

Europe Bioreactors Market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:

Europe Bioreactors Market Share, By Cell, 2014-2025, (USD Million)

  • Mammalian cells
  • Bacterial cells
  • Yeast cells
  • Others

Europe Bioreactors Market Size, By Molecule, 2014-2025, (USD Million)

  • Monoclonal antibodies
  • Vaccines
  • Recombinant protein
  • Stem cell
  • Gene therapy
  • Others

Europe Bioreactors Market Value, By Technology, 2014-2025, (USD Million)

  • Wave-induced motion SUB
  • Stirred SUB
  • Stirred-use bubble column
  • Others
Europe Bioreactors Market Trends, By End-use, 2014-2025, (USD Million)
  • Research and development (R&D) organizations
  • Biopharma manufacturers
  • Contract manufacturing organizations (CMOs)

The above information is provided for the following region and countries:

  • Europe
    • Germany
    • UK
    • Spain
    • Italy
    • France
    • The Netherlands
    • Denmark
    • Russia
    • Poland
    • Sweden
    • Norway